<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bavarian Nordic — News on 6ix</title>
<link>https://6ix.com/company/bavarian-nordic</link>
<description>Latest news and press releases for Bavarian Nordic on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 05:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bavarian-nordic" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836231478dffbe2df14245f.webp</url>
<title>Bavarian Nordic</title>
<link>https://6ix.com/company/bavarian-nordic</link>
</image>
<item>
<title>Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-receives-swissmedic-approval-for-chikungunya-vaccine-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-receives-swissmedic-approval-for-chikungunya-vaccine-1</guid>
<pubDate>Thu, 16 Apr 2026 05:30:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above. The virus-like particle (VLP) single-dose vaccine is the first chikungunya vaccine to receive approval in Switzerland and was approved following review of the regulatory dossier submitt</description>
</item>
<item>
<title>Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-submits-data-to-ema-to-extend-mpox-and-smallpox-vaccine-approval-to-children-aged-2-11-years-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-submits-data-to-ema-to-extend-mpox-and-smallpox-vaccine-approval-to-children-aged-2-11-years-1</guid>
<pubDate>Fri, 27 Mar 2026 07:00:00 GMT</pubDate>
<description>Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the MVA-BN® mpox and smallpox vaccine indication to include children aged 2 to 11 years. The submission is based on positive topline results from</description>
</item>
<item>
<title>Bavarian Nordic Launches Next Tranche of Share Buy-Back Program</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-launches-next-tranche-of-share-buy-back-program-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-launches-next-tranche-of-share-buy-back-program-1</guid>
<pubDate>Thu, 12 Mar 2026 06:51:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche, completed in early February 2026, comprised buy-back of shares for DKK 150 million. The second tranche will comprise buy-back of shares for DKK 200 million, also to be held as treasury stock for the purpose of adjusting the capital structure. The s</description>
</item>
<item>
<title>Bavarian Nordic Publishes Annual Report 2025</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-publishes-annual-report-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-publishes-annual-report-2025-1</guid>
<pubDate>Thu, 12 Mar 2026 06:39:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, 2026. The report is attached and available on www.bavarian-nordic.com. “Our 2025 annual report confirms the strong preliminary results reported last month and we are well underway in the execution of our plans for 2026 to deliver continued growth in our Travel Health business. Organi</description>
</item>
<item>
<title>Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-and-serum-institute-of-india-expand-strategic-partnership-with-chikungunya-vaccine-manufacturing-agreement-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-and-serum-institute-of-india-expand-strategic-partnership-with-chikungunya-vaccine-manufacturing-agreement-1</guid>
<pubDate>Wed, 11 Mar 2026 07:30:00 GMT</pubDate>
<description>The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.Expanded collaboration provides future co-development opportunities. COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine</description>
</item>
<item>
<title>Paul Chaplin Steps Down as CEO of Bavarian Nordic</title>
<link>https://6ix.com/company/bavarian-nordic/news/paul-chaplin-steps-down-as-ceo-of-bavarian-nordic-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/paul-chaplin-steps-down-as-ceo-of-bavarian-nordic-1</guid>
<pubDate>Mon, 02 Mar 2026 06:42:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO. Paul Chaplin has been with Bavarian Nordic since 1999 and was appointed CEO in 2014. He has led the develo</description>
</item>
<item>
<title>Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-receives-usd-22-070000528</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-receives-usd-22-070000528</guid>
<pubDate>Wed, 18 Feb 2026 07:00:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine, MVA-BN®. This order, awarded under the existing 10-year contract framework established with PHAC in 2022, will ensure manufacturing of bulk vaccine product in 2026, with filling and supply of the final drug product to occur later. With this award, Bavarian Nordic has now secured</description>
</item>
<item>
<title>Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-reports-preliminary-2025-064300261</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-reports-preliminary-2025-064300261</guid>
<pubDate>Thu, 12 Feb 2026 06:43:00 GMT</pubDate>
<description>Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions. COPENHAGEN, Denmark, February 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for</description>
</item>
<item>
<title>Bavarian Nordic – Completion of Share Buy-Back Program</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-completion-share-buy-082100137</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-completion-share-buy-082100137</guid>
<pubDate>Mon, 09 Feb 2026 08:21:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure. The progra</description>
</item>
<item>
<title>Bavarian Nordic – Transactions in Connection with Share Buy-Back Program</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-transactions-connection-share-075400927</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-transactions-connection-share-075400927</guid>
<pubDate>Mon, 02 Feb 2026 07:54:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, whic</description>
</item>
<item>
<title>Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-signs-distribution-agreement-070000596</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-signs-distribution-agreement-070000596</guid>
<pubDate>Fri, 23 Jan 2026 07:00:00 GMT</pubDate>
<description>Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccinePotential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil. Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the</description>
</item>
<item>
<title>Bavarian Nordic Launches Planned Share Buy-Back Program</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-launches-planned-share-070900902</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-launches-planned-share-070900902</guid>
<pubDate>Wed, 07 Jan 2026 07:09:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche will comprise buy-back of shares for up to DKK 150 million, which will be held as treasury stock for the purpose of adjusting the capital structure. The share buy-back program is initiated pursuant to the authorization gr</description>
</item>
<item>
<title>Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-establishes-long-term-194100963</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-establishes-long-term-194100963</guid>
<pubDate>Thu, 18 Dec 2025 19:41:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, December 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management as part of the annual remuneration as laid out in the Remuneration Policy, adopted at the annual general meeting. Members of the Executive Management are granted performance restricted stock units (Performance RSUs), subject to the successful achievement of relevant Key Performance Indicators (KPI’s),</description>
</item>
<item>
<title>Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic</title>
<link>https://6ix.com/company/bavarian-nordic/news/heidi-hunter-appointed-vice-chair-073000713</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/heidi-hunter-appointed-vice-chair-073000713</guid>
<pubDate>Wed, 17 Dec 2025 07:30:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm</description>
</item>
<item>
<title>Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-launch-share-buy-070100859</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-launch-share-buy-070100859</guid>
<pubDate>Tue, 02 Dec 2025 07:01:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months. This decision should be viewed in the context of a current strong cash position, resulting from the recent sale of the Priority Review Voucher and a continued positive cash flow from operations. As of September 30, 2025, securities, cash and cash equivalents were DKK 2,978 million, of which</description>
</item>
<item>
<title>Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-host-shareholder-information-200000048</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-host-shareholder-information-200000048</guid>
<pubDate>Wed, 26 Nov 2025 20:00:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, November 26, 2025 – Bavarian Nordic A/S invites its shareholders for a meeting and dialogue with the company’s board and management, who will provide the state of business and give a recap of the company’s strategy. The meeting will take place at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, DK-1577 Copenhagen V, Denmark on December 11, 2025 from 09:00 am to 10:30 am CET. The meeting will be held in English. Anyone who is registered as a shareholder in the company’</description>
</item>
<item>
<title>Bavarian Nordic Announces Interim Results for the First Nine Months of 2025</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-announces-interim-results-063700075</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-announces-interim-results-063700075</guid>
<pubDate>Fri, 14 Nov 2025 06:37:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand fo</description>
</item>
<item>
<title>Bavarian Nordic Announces Changes to the Board of Directors</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-announces-changes-board-194500561</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-announces-changes-board-194500561</guid>
<pubDate>Thu, 13 Nov 2025 19:45:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, November 13, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Chair of the Board, Luc Debruyne has decided to step down from the board with immediate effect. The Board has appointed Vice Chair Anne Louise Eberhard as new Chair of the Board. “After careful reflection on both the process and the outcome of the recent takeover attempt, I have decided to step down to enable the board of Bavarian Nordic to focus on the company’s next phase of development. I have deep a</description>
</item>
<item>
<title>Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley</title>
<link>https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-announces-major-shareholder-200000614</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/bavarian-nordic-announces-major-shareholder-200000614</guid>
<pubDate>Mon, 10 Nov 2025 20:00:00 GMT</pubDate>
<description>COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines t</description>
</item>
<item>
<title>Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed</title>
<link>https://6ix.com/company/bavarian-nordic/news/consortium-consisting-of-nordic-capital-and-permira-announces-preliminary-result-of-the-takeover-offer-to-shareholders-of-bavarian-nordic-and-that-the-offer-is-withdrawn-and-will-not-be-completed-1</link>
<guid isPermaLink="true">https://6ix.com/company/bavarian-nordic/news/consortium-consisting-of-nordic-capital-and-permira-announces-preliminary-result-of-the-takeover-offer-to-shareholders-of-bavarian-nordic-and-that-the-offer-is-withdrawn-and-will-not-be-completed-1</guid>
<pubDate>Thu, 06 Nov 2025 14:03:00 GMT</pubDate>
<description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 6 November, 2025 – With reference to company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary board-recommended public takeover offer to acquire all o</description>
</item>
</channel>
</rss>